Karim Budhwani

Karim Budhwani has extensive experience in the business and medical fields. Karim has been the CEO of CerFlux since 2018 and of elixir international since 1998. Karim has also been a Visiting Scientist at the UAB Hugh Kaul Personalized Medicine Institute since 2022, at the UAB School of Medicine since 2018, and at Coe College since 2010. Additionally, they have served as a Strategic Vision Advisor for TruSpin Nanomaterial Innovation since 2019, a Founding Member of the Business Journals Leadership Trust since 2019, an Advisory Board Member for the O'Neal Comprehensive Cancer Center at UAB since 2019, and a Venture Partner for FundRx since 2018. Karim is also a member of the Medical Advisory Council for the Breast Cancer Research Foundation of Alabama since 2022.

Karim Budhwani obtained a B.A. Magna Cum Laude from Coe College in 1993, majoring in Computer Science, Economics, and Business Administration with a minor in Math. In 2013, they received a Graduate Level Certificate in Translational & Molecular Sciences (TMS) from The University of Alabama at Birmingham. Karim also obtained a GATE: Graduate Automotive Technology Education Certification from the U.S. Department of Energy in 2013. In 2014, they earned a Master of Science - MS in Biomedical/Medical Engineering from the University of Alabama at Birmingham and in 2016, they obtained an International Management Audit Certification from The London School of Economics and Political Science (LSE). Karim also received an MCAD Certification from Microsoft in 2004. In 2018, Karim Budhwani earned a Doctor of Liberal Arts - DLA from Coe College and a Doctor of Philosophy - PhD in Materials Science and Engineering from the University of Alabama at Birmingham.